>
UPDATE: Israel Launches Gaza Strikes, Peace Plan in Question
Gavin Newsom melts down as Pentagon plans to fire artillery shells over California highway during...
The watershed moment Trump changed course on Israel after Netanyahu shattered their...
Brazen thieves drop priceless Eugénie crown outside the Louvre in Paris during jaw-dropping...
3D Printed Aluminum Alloy Sets Strength Record on Path to Lighter Aircraft Systems
Big Brother just got an upgrade.
SEMI-NEWS/SEMI-SATIRE: October 12, 2025 Edition
Stem Cell Breakthrough for People with Parkinson's
Linux Will Work For You. Time to Dump Windows 10. And Don't Bother with Windows 11
XAI Using $18 Billion to Get 300,000 More Nvidia B200 Chips
Immortal Monkeys? Not Quite, But Scientists Just Reversed Aging With 'Super' Stem Cells
ICE To Buy Tool That Tracks Locations Of Hundreds Of Millions Of Phones Every Day
Yixiang 16kWh Battery For $1,920!? New Design!
Find a COMPATIBLE Linux Computer for $200+: Roadmap to Linux. Part 1
A 13-year-old girl who was left completely bald from her alopecia has made an incredible transformation after taking an arthritis drug.
The unidentified teenager, from Brazil, had slowly been losing her hair for five years and standard medications failed to help. Doctors tried tofacitinib as a last-resort.
Tests of the drug, marketed as Xeljanz, have shown it can help alopecia patients regrow their hair – but it is not yet licensed as a conventional treatment.
After just four months, the girl regained a significant amount of her hair. She was left with thick, brown locks within two years of taking tofacitinib.
The results add to the evidence that the drug could offer hope for millions of patients around the world with alopecia, who have slim chances of making a full recovery.
Tofacitinib is routinely given to patient with rheumatoid arthritis, which is caused by inflammation. Dermatologists say the type of alopecia the girl had is caused by the same process.
Medical student Rachel Berbert Ferreira, at Centro Universitario Cesumar, was the senior author of the paper in Clinical Case Reports.